OGOnur Serdar Gençler

Onur Serdar Gençler

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Onur Serdar Gençler has a total of 34 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Parkinson's Disease with REM Sleep Behavior Disorder and Tension-Type Headache

    by Aygül Güneş, Onur Serdar Gençler

    Parkinson’s disease (PD) is the second most common neurodegenerative disorder. Among its non-motor symptoms (NMSs), sleep disturbances represent a clinically significant symptom. Clonazepam is generally recommended as a first-line treatment option for REM sleep behavior disorder (RBD). However, the evidence supporting the use of melatonin has been steadily increasing. Although pain is also one of the most common NMS in patients with PD, the relationship between PD and primary headache disorders has not been thoroughly investigated. Sleep disorders and headache are known to involve overlapping brain structures and shared neurobiological pathways. While prioritizing neurodegeneration within the dopaminergic system and selecting agents aimed at enhancing dopaminergic activity, clinicians should remain mindful of the potential risks associated with these therapies. Moreover, the use of dopamine agonists, particularly in older patients, may precipitate or exacerbate hallucinations and impulse control disorders. Likewise, in patients with comorbid generalized anxiety disorder, the initiation of selective serotonin reuptake inhibitors may worsen concomitant restless legs syndrome and may further aggravate insomnia. In PD cases accompanied by RBD and coexisting primary headache, mindful approach of the patient’s symptoms is essential in order to establish the correct diagnosis and determine the most appropriate therapeutic strategy. We present a challenging case in which this diagnostic and therapeutic complexity was particularly evident. Our case was a 54-year-old middle-aged man who was diagnosed with PD and concurrent RBD, and tension-type headache who also had psychiatric comorbidities. As mentioned by our cases, the most reliable and effective approach to the management of such complex situations is a multidisciplinary one.

  • Huntington Hastalığı Tedavisi

    by Onur Serdar Gençler

    Huntington hastalığı (HH), tam penetransa sahip, otozomal dominant (OD) kalıtım gösteren ilerleyici bir nörodejeneratif hastalıktır. Hastalığın klinik belirtileri ilerleyici motor, psikiyatrik ve kognitif bozukluktur. Motor semptomlardan kore, en göze çarpan bulgularındandır. Mutant huntingtin geni (mHTT), HH’den sorumlu gen olup 40 ve üzeri CAG tekrarı tam penetranslı hastalık gelişimi ile ilişkilidir. Günümüzde HH’nin, mHTT geni ya da mHTT agregatlarını hedef alan kanıtlanmış bir hastalık modifiye edici, kesin bir tedavisi bulunmamaktadır. Hali hazırda kullanılan ilaçlar ile esas olarak HH’nin motor, kognitif ve psikiyatrik semptomlarını hafifletmek ve hastaların yaşam kalitelerini yükseltmek hedeflenmektedir. Son yıllarda hastalığın moleküler ve genetik düzeyde anlaşılmasına yönelik klinik çalışmalar yapılmaktadır. Bu çalışmalar hastalık modifiye edici molekülleri de kapsamaktadır. Bu gelişmeler HH’de yeni ve başarılı tedaviler açısından umut vadetmektedir. Huntington hastalığı tedavisinin ele alınacağı bu bölümde, HH’ye yönelik güncel semptomatik tedavi yaklaşımlarının yanı sıra, hastalık modifiye edici tedaviler, tamamlanmış ve hali hazırda yürütülen klinik araştırmalar, genetik çalışmalar ve geleceğe dönük tedavi yaklaşımları kapsamlı bir şekilde ele alınacaktır.

  • Open Access

    The potential role of serum and urine galectin-3 values in the diagnosis and staging of Parkinson’s disease

    by Miray Erdem, Derya Ozdogru, Elif Banu Soker, Burak Ademoglu, Nevzat Unal, Onur Serdar Gencler

    Parkinson’s disease (PD) is a progressive neurodegenerative disorder characterised by both motor and nonmotor symptoms. Galectin-3, a protein involved in the regulation of inflammatory responses, has emerged as a potential contributor to neurodegenerative processes. This study aimed to measure serum and urinary galectin-3 levels in patients with PD and to evaluate the associations of this biomarker with disease stages and clinical symptoms. The present cross-sectional study included 30 PD patients and 29 healthy controls. Galectin-3 levels in serum and urine samples were measured via Enzyme-Linked Immunosorbent Assay (ELISA). The clinical data recorded included demographic information, Hoehn and Yahr (H&Y) stage, Unified Parkinson’s Disease Rating Scale (UPDRS) motor score, nonmotor symptom score (NMS), and total dopaminergic treatment dose parameters. Multivariate analyses were adjusted for age and sex due to demographic differences between groups. Serum galectin-3 optical density (OD) levels (0.2 [0.1–1.4]) and urinary galectin-3 OD levels (0.2 [0.1–0.6]) were significantly higher in PD patients than in controls (p < 0.050). Serum and urinary galectin-3 concentration (C) values were also elevated in the PD group. A moderate negative correlation was observed between serum galectin-3 levels and both the H&Y stage (r = − 0.418, p = 0.021) and the UPDRS motor score (r = − 0.541, p = 0.002). After adjusting for age and sex, serum galectin-3 C remained independently associated with motor severity. ROC analysis revealed that serum galectin-3 levels demonstrated promising diagnostic performance, with high specificity and sensitivity in distinguishing patients with PD from healthy controls (AUC = 0.716, p = 0.001). The serum/urine galectin-3 concentration ratio also showed significant discriminative value (AUC = 0.722, p = 0.035). Our findings suggest that elevated levels of galectin-3 in serum and urine are associated with Parkinson’s disease and may reflect underlying neuroinflammatory mechanisms contributing to its pathophysiology. The diagnostic performance of galectin-3 markers remained robust even after adjusting for age and sex. However, the strict exclusion criteria and the age imbalance between groups may limit the generalizability of these results to broader clinical populations. Therefore, these findings should be considered exploratory and require confirmation through larger, longitudinal studies to determine their diagnostic and prognostic utility.


  • Open Access

    The potential of visual evoked potentials latency and amplitude to be a subclinical predictor of clinical prognosis in multiple sclerosis

    by Elif Banu Soker, Miray Erdem, Derya Ozdogru, Onur Serdar Gencler, Onder Yesiloglu, Halit Fidanci

    Background: Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system characterized by focal demyelinating lesions, axonal dysfunction/degeneration, and gliosis, which can lead to various clinical disabilities. Visual evoked potentials (VEP) is sensitive and repeatable techniques capable of monitoring significant short-term changes in neuroaxonal integrity and alterations in nerve conduction triggered by acute optic neuritis. Aim: This study aims to evaluate whether VEP latency and amplitude could serve as subclinical predictors of clinical outcomes in MS patients over short-term follow-ups. Methods: This study was planned to include MS patients diagnosed according to the McDonald Criteria 18 who did not have any psychiatric, neurological, or ocular disorders that could interfere with the main purpose. The VEP test was performed for routine evaluation of demyelination or axonal damage. Results: A total of 83 patients were included in the study, with a mean age of 33.6 ± 9.3 years. Of all the patients, 54 were female (65.1%) and 29 were male (34.9%). Right pattern reversal visual evoked potential (PVEP) P100 (OR for PVEP1: 0.802, p = 0.001; OR for PVEP2: 0.879, p = 0.002) was statistically significant in showing right VEP abnormality at both baseline and at 6 months. Left VEP abnormalities were associated with left PVEP P100 at PVEP1 (OR: 0.852, p = 0.003) and left PVEP N75 at PVEP2 (OR: 0.935, p = 0.029). Conclusion: VEPs have the potential to predict short-term subclinical stability or progression, making them valuable candidates for early treatment adjustments and evaluating future pharmacotherapy-supported remyelination.


  • Omuz Bölgesinin Sinir Yaralanmaları

    by Onur Serdar Gençler

    Omuz bölgesi sinir yaralanmaları; penetran travmalar, kompresyon, traksiyon ve cerrahi işlemler gibi çeşitli etkenler sonucunda glenohumeral eklem çevresindeki yapılarda meydana gelen nörolojik hasarları kapsamaktadır. Şiddetli akson yaralanmalarında distal segmentte Wallerian dejenerasyonu gelişirken, proksimal hasar ilk Ranvier düğümüne kadar ilerler ve fonksiyonel geri kazanım için reinnervasyonun 12-18 ay içinde tamamlanması gerekir. Klinik değerlendirmelerde hasarın şiddetini belirlemek amacıyla Seddon ve histopatolojik temelli Sunderland sınıflandırma sistemleri kullanılmakta; en hafif evre olan nörapraksiden, destek dokularının ve sinir bütünlüğünün tamamen kaybolduğu nörotmezise kadar geniş bir yelpaze tanımlanmaktadır. Tanı süreçlerinde klinik ve nörolojik muayenenin yanı sıra elektronöromiyografi (ENMG), ultrasonografi ve manyetik rezonans görüntüleme (MRG) yöntemlerinden faydalanılmaktadır. Tedavi yaklaşımlarında, düşük dereceli sinir yaralanmaları (Sunderland I-III) için fizik tedavi ve egzersiz gibi konservatif metotlar öncelik kazanırken; ileri derece yaralanmalarda (Sunderland IV-V) veya tıbbi tedaviye dirençli vakalarda nörolizis, greftleme ve sinir transferi gibi cerrahi müdahaleler uygulanmaktadır. Ayrıca, omuz dislokasyonları ve rotator manşet onarımları gibi açık veya artroskopik operasyonlar sırasında aksiller, supraskapuler ve muskulokütanöz sinirler yüksek iyatrojenik hasar riski taşımaktadır. Nerve injuries of the shoulder region encompass neurological damages occurring in the structures around the glenohumeral joint due to various factors such as penetrating trauma, compression, traction, and surgical procedures. In severe axonal injuries, Wallerian degeneration develops in the distal segment, while proximal damage progresses up to the first node of Ranvier, and reinnervation must occur within 12-18 months for functional recovery. In clinical evaluations, Seddon and histopathological-based Sunderland classification systems are utilized to determine the severity of injury, defining a wide spectrum from neurapraxia, the mildest stage, to neurotmesis, where supporting tissues and nerve integrity are completely lost. In diagnosis processes, electronuromyography (ENMG), ultrasonography, and magnetic resonance imaging (MRI) methods are utilized alongside clinical and neurological examinations. Regarding treatment approaches, conservative methods such as physical therapy and exercise gain priority for low-grade nerve injuries (Sunderland I-III), whereas surgical interventions like neurolysis, grafting, and nerve transfer are required for advanced injuries (Sunderland IV-V) or cases resistant to medical treatment. Furthermore, during open or arthroscopic operations such as shoulder dislocations and rotator cuff repairs, the axillary, suprascapular, and musculocutaneous nerves carry a high risk of iatrogenic damage.

  • Open Access

    Omuz Eklemi El Kitabı

    by Tamer Erener, Göker Yurdakul, İbRahim Altun, Abdulaziz Temiz, Salih Ergün, Gökhan Peker, Emre Atmaca, Kadir Eren Biçer, Pınar Kaya Subaşı, İsMail Yükünç, et al.

    Omuz Anatomisi ve Biyomekaniği Tamer ERENER Omuz Eklemi Muayenesi ve Klinik Değerlendirilmesi Göker YURDAKUL Omuz Çevresi Kırıkları İbrahim ALTUN Glenohumeral Çıkıklar İbrahim ALTUN Omuz Eklem Patolojilerinde Tanı ve Görüntüleme Abdulaziz TEMİZ Rotator Manşet Yaralanmaları Salih ERGÜN Akromiyoklaviküler Eklem Yaralanmaları Gökhan PEKER Labral Patolojiler Emre ATMACA Omuz İnstabiliteleri Ve Tedavi Yöntemleri Kadir Eren BİÇER Donuk Omuz (Adheziv Kapsülit) Bilgehan TAĞRİKULU Donuk Omuzda Rehabilitasyon Pınar KAYA SUBAŞI Kalsifik Tendinopatiler İsmail YÜKÜNÇ Omuz Artroskopisi Endikasyonları Abdullah İYİGÜN Omuz Artriti Ve Artroplastisi Eren İMAMOĞLU Omuz Bölgesinin Sinir Yaralanmaları Onur Serdar GENÇLER

  • Open Access

    Glioblastoma Multiforme With CDKN2A, Loss of PTEN and EGFR Amplification, and Diffuse Distant Organ Metastasis Treated With Six Lines of Therapy: A Case Report and Literature Review

    by Ferit Aslan, Elif Günaydın, Fisun Yukruk, İnanç Güvenç, Onur Serdar Gençler

    In glioblastoma multiforme (GBM) cases, the tumor usually remains limited to the central nervous system in the expected disease course. Here, we discuss the case of a 41-year-old male patient who presented with extracranial spread, which has been reported in a limited number of cases in the literature. The patient received six lines of treatment including radiotherapy with temozolomide, irinotecan-bevacizumab combination, lomustine, erlotinib, everolimus, and weekly carboplatin-paclitaxel. In addition to systemic treatment, the patient underwent radiotherapy and surgery twice. Despite presenting with features consistent with a poor prognosis and extensive multi-organ metastasis, the patient achieved an overall survival of 25 months. In our view, the clinical course of our case, the follow-up, and the treatment process will add to the literature.


  • Comparison of pramipexole versus ropinirole in the treatment of Parkinson’s disease

    by Onur Serdar Gencler, Nese Oztekin, Mehmet Fevzi Oztekin

    Parkinson’s disease is a progressive neurodegenerative disease characterized by motor and non-motor symptoms. Levodopa is the most effective drug in the symptomatic treatment of the disease. Dopamine receptor agonists provide sustained dopamin-ergic stimulation and have been found to delay the initiation of levodopa treatment and reduce the frequency of various motor complications due to the long-term use of levodopa. The primary aim of this study was to compare the efficacy of potent nonergoline dopamine agonists pramipexole and ropinirole in both “dopamine agonist monotherapy group” and “levodopa add-on therapy group” in Parkinson’s disease. The secondary aims were to evaluate the effects of these agents on depression and the safety of pramipexole and ropinirole. A total of 44 patients aged between 36 and 80 years who were presented to the neurology clinic at Ministry of Health Diskapi Yildirim Beyazit Training and Research Hospital, Ankara, Turkey and were diagnosed with idiopathic Parkinson’s disease, were included into this randomized parallel-group clinical study. Dopamine agonist monotherapy and levodopa add-on therapy patients were randomized into two groups to receive either pramipexole or ropinirole. The maximum daily dosages of pramipexole and ropinirole were 4.5 mg and 24 mg respectively. Patients were followed for 6 months and changes on Unified Parkinson’s Disease Rating Scale, Clinical Global Impression-severity of illness, Clinical Global Impression-improvement, Beck Depression Inven­tory scores, and additionally in advanced stages, changes in levodopa dosages were evaluated. Drug associated side effects were noted and compared. In dopamine agonist monotherapy group all of the subsections and total scores of Unified Parkinson’s Disease Rating Scale and Clinical Global Impression-severity of illness of the pramipexole subgroup showed significant improvement particularly at the end of the sixth month. In the pramipexole subgroup of levodopa add-on therapy group, there were significant improvements on Clinical Global Impression-severity of illness and Beck Depression Inventory scores, but we found significant improvement on Clinical Global Impression-severity of illness score at the end of the sixth month in ropinirole subgroup too. The efficacy of pramipexole and ropinirole as antiparkinsonian drugs for monotherapy and levodopa add-on therapy in Parkinson’s disease and their effects on motor complications when used with levodopa treatment for add-on therapy have been demonstrated in several previous studies. This study supports the effectiveness and safety of pramipexole and ropinirole in the monotherapy and levodopa add-on therapy in the treatment of Parkinson’s disease.